13D Filing: Baker Bros. Advisors Owns 18% of Bellicum Pharmaceuticals, Inc (BLCM)

Page 1 of 9

At Insider Monkey, we closely monitor the moves made by activist investors. Their targets are often undervalued stocks with firm foundations that for one reason or another have failed to execute. At times, all it takes is a fresh outlook and a slight tweak to completely alter the makeup and efficiency of a company, and activists can provide this. They also shine a spotlight on shareholder value creation, which can be neglected by entrenched management who often have their priorities elsewhere. Below and on the following pages we have embedded the latest 13D activist filing related to Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), which was recently submitted by Julian and Felix Bakers‘ healthcare-focused hedge fund Baker Bros. Advisors.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Baker Bros. Advisors LP2.   4,865,647 4,865,647 0 4,865,647 18.0%
Baker Bros. Advisors (GP) LLC2. 4,865,647 4,865,647 0 4,865,647 18.0%
Julian C. Baker2.   4,865,647 4,865,647 0 4,865,647 18.0%
Felix J. Baker2.   4,865,647 4,865,647 0 4,865,647 18.0%

Follow Julian Baker And Felix Baker's Baker Bros. Advisors

Page 1 of 9 SEC Filing






Under the Securities Exchange Act of

(Amendment No. 1)*

Bellicum Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, Par Value $0.01 Per Share

(Title of Class of Securities)


(CUSIP number)

Alexandra A. Toohey

Chief Financial Officer

Baker Bros. Advisors LP

667 Madison Avenue, 21st Floor

New York, NY 10065

(212) 339-5690

(Name, address and telephone
number of person authorized to receive notices and communications)

January 15, 2016

(Date of event which requires filing of
this statement)

the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.

(Continued on the following pages)

Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to
be sent.

*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

Page 1 of 9